Navigating Regulatory Challenges and Ensuring Safety in the Psychedelics Industry
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Navigating Regulatory Challenges and Ensuring Safety in the Psychedelics Industry
-
ナレーター：
-
著者：
このコンテンツについて
"Balancing Medical Promise and Regulatory Complexity in the Psychedelics Landscape"
The "Psychedelics Capital Podcast" host Ross O'Brien from Bonaventure Equity interviews Michael Werner from Holland & Knight, discussing the regulatory landscape for psychedelics. Michael, a partner at the law firm, explains that while the FDA sees itself as a public health agency focused on ensuring safe and effective products, the DEA approaches controlled substances like psychedelics from a law enforcement perspective due to their potential dangers. He highlights that while many drugs, including psychedelics, have potential benefits, the FDA emphasizes the importance of rigorous clinical trials to establish their safety and efficacy, particularly in a landscape where recreational and unregulated use is also prevalent.
Produced by PodConx
Ross O'Brien - https://www.linkedin.com/in/rossobrien/
Bonaventure Equity - https://link.bve.vc/Visit-Us
Michael Warner - https://www.linkedin.com/in/michael-werner-a402189/
Holland & Knight - https://www.hklaw.com/